Toward the Broad Adoption of 3D Tumor Models in the Cancer Drug Pipeline
详细信息 查看全文
- 作者：Megan C. Cox ; Laura M. Reese ; Lissett R. Bickford ; Scott S. Verbridge
- 刊名：ACS Biomaterials Science & Engineering
- 出版年：2015
- 出版时间：October 12, 2015
- 年：2015
- 卷：1
- 期：10
- 页码：877-894
- 全文大小：1088K
- ISSN：2373-9878
文摘
Despite a cost of approximately $1 billion to develop a new cancer drug, about 90% of drugs that enter clinical trials fail. A tremendous opportunity exists to streamline the drug selection and testing process, and innovative approaches promise to reduce the burdensome cost of health care for those suffering from cancer. There is great potential for 3D models of human tumors to complement more traditional testing methods; however, the shift from 2D to 3D assays at early stages of the drug discovery and development process is far from widely accepted. 3D platforms range from simple tumor spheroids to more complex microfluidic hydrogels that better mimic the tumor microenvironment. While several companies have developed and patented advanced high-throughput 3D platforms for drug screening, their cost and complexity have limited their adoption as an industry standard. In this review, we will highlight the various tumor platforms that have been developed, emphasizing the approaches that have successfully led to commercial products. We will then consider potential directions toward more relevant tumor models, advantages of the adoption of such platforms within the drug development and screening process, and new opportunities in personalized medicine that such platforms will uniquely enable.